Comphya

Executive Summary

Comphya is a Swiss digital health and neuromodulation company pioneering CaverSTIM™, an implantable device designed to restore erectile nerve function after radical prostatectomy. The system is implanted during surgery and delivers sub-sensory electrical stimulation to promote nerve rehabilitation, addressing a significant unmet need in post-prostate cancer recovery. With a Phase 1 clinical stage, the company is advancing its technology through early feasibility studies, leveraging its proprietary neuromodulation platform. Comphya's solution targets the high prevalence of erectile dysfunction following prostate cancer surgery, affecting over 50% of patients, and could significantly improve quality of life. The company's focus on precision nerve stimulation and its potential for commercialization in urology and sexual health markets position it as an innovative player in the neurorehabilitation space, though it remains in early clinical validation.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 Clinical Trial Interim Data Readout70% success
• Q1 2027Series B Funding Round Completion60% success
• Q2 2027Strategic Partnership with Urology Device Company50% success